[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633777":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":41,"centralContacts":45,"locations":51,"responsibleParty":112,"collaborators":30,"id":114,"slug":30,"hasResults":115,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":115,"sex":121,"minAge":122,"maxAge":123,"enrollmentInfo":124,"targetDuration":30,"studyType":127,"phases":128,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":54,"whyStopped":30,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":148},{"fullName":5,"class":6},"Amgen","INDUSTRY",[8,15,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Dose Exploration (Part 1)","EXPERIMENTAL","Multiple dose levels of ZL-1310 will be explored in combination with tarlatamab administered intravenously (IV).",[13,14],"Drug: ZL-1310","Drug: Tarlatamab",{"label":16,"type":10,"description":17,"interventionNames":18},"Dose Expansion (Part 2)","ZL-1310 will be administered IV at the selected maximum tolerated combination dose (MTCD) or recommended phase 2 dose (RP2D) in combination with tarlatamab administered IV.",[13,14],{"label":20,"type":10,"description":21,"interventionNames":22},"Triplet Combination (Part 3)","ZL-1310 will be administered at MTCD or RP2D in combination with tarlatamab and an anti-PD-L1 (durvalumab) each administered IV.",[13,14,23],"Drug: Durvalumab",[25,31,37],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","ZL-1310","ZL-1310 will be administered as an IV infusion.",[16,9,20],null,{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"Tarlatamab","Tarlatamab will be administered as an IV infusion.",[16,9,20],[36],"IMDELLTRA",{"type":26,"name":38,"description":39,"armGroupLabels":40,"otherNames":30},"Durvalumab","Durvalumab will be administered as an IV infusion.",[20],[42],{"name":43,"affiliation":5,"role":44},"MD","STUDY_DIRECTOR",[46],{"name":47,"role":48,"phone":49,"phoneExt":30,"email":50},"Amgen Call Center","CONTACT","866-572-6436","medinfo@amgen.com",[52,64,74,84,94,103],{"facility":53,"status":54,"city":55,"state":55,"zip":56,"country":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":30},"New York University Cancer Institute","RECRUITING","New York","10016","United States",{"type":59,"coordinates":60},"Point",[61,62],-74.00597,40.71427,{"lat":62,"lon":61},{"facility":65,"status":54,"city":66,"state":67,"zip":68,"country":57,"cosmosGeoPoint":69,"geoPoint":73,"contacts":30},"Baptist Cancer Center","Memphis","Tennessee","38120",{"type":59,"coordinates":70},[71,72],-90.04898,35.14953,{"lat":72,"lon":71},{"facility":75,"status":54,"city":76,"state":77,"zip":78,"country":57,"cosmosGeoPoint":79,"geoPoint":83,"contacts":30},"Next Virginia","Fairfax","Virginia","22031",{"type":59,"coordinates":80},[81,82],-77.30637,38.84622,{"lat":82,"lon":81},{"facility":85,"status":54,"city":86,"state":30,"zip":87,"country":88,"cosmosGeoPoint":89,"geoPoint":93,"contacts":30},"Adana Sehir Egitim ve Arastirma Hastanesi","Adana","01370","Turkey (Türkiye)",{"type":59,"coordinates":90},[91,92],35.32531,36.98615,{"lat":92,"lon":91},{"facility":95,"status":54,"city":96,"state":30,"zip":97,"country":88,"cosmosGeoPoint":98,"geoPoint":102,"contacts":30},"Hacettepe Universitesi Tip Fakultesi Hastanesi","Ankara","06230",{"type":59,"coordinates":99},[100,101],32.85427,39.91987,{"lat":101,"lon":100},{"facility":104,"status":54,"city":105,"state":30,"zip":106,"country":88,"cosmosGeoPoint":107,"geoPoint":111,"contacts":30},"Izmir Ekonomi Universitesi Medical Point Hastanesi","Izmir","35575",{"type":59,"coordinates":108},[109,110],27.13838,38.41273,{"lat":110,"lon":109},{"type":113,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100633777",false,"NCT07531095","Study of Tarlatamab + ZL-1310 +\u002F- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)","A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With ZL-1310 With or Without Anti-PD-L1 in Participants With Small Cell Lung Cancer","DeLLphi-313","Inclusion Criteria:\n\n* Age ≥ 18 years (or ≥ legal age within the country if it is older than 18 years) at the time of signing the informed consent.\n* Participants with Histologically or cytologically confirmed SCLC:\n* For Part 1, participants must have SCLC that has progressed or recurred following at least 1 line of platinum-based anti-cancer therapy.\n* For Parts 1 and 2, participants must have progressed or recurred following at least 1 line of platinum-based therapy. No prior tarlatamab is allowed in Cohort 2-1.\n* For Part 3, participants must have extensive-stage SCLC (ES-SCLC) with no prior systemic treatment other than 1 cycle of platinum-based chemotherapy.\n\nNote: Participants with prior treatment for limited-stage SCLC (LS-SCLC) before diagnosis of ES SCLC are permitted.\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* At least 1 measurable lesion as defined per RECIST v1.1 within 21-day screening period, not previously irradiated.\n* Adequate organ function (hematological, coagulation, renal, hepatic, pulmonary, and cardiac function).\n\nExclusion Criteria:\n\n* Symptomatic CNS metastases. Participants with treated brain metastases are eligible provided they meet the criteria specified in the protocol.\n* History of interstitial lung disease (ILD)\u002Fpneumonitis.\n* Received thoracic radiation therapy within 90 days prior to first dose of trial intervention.\n* Prior therapy with any delta-like ligand 3 (DLL3)-directed therapy.\n* Prior exposure to topoisomerase I inhibitors or antibody-drug conjugate (ADC) with topoisomerase I inhibitor payload.\n* Receiving strong CYP3A4 or CPY2D6 inhibitors within 14 days or 5 half-lives (whichever is longer) before the first dose of trial treatment.\n* Enrollment in any tarlatamab clinical trial.","ALL","18 Years","99 Years",{"count":125,"type":126},160,"ESTIMATED","INTERVENTIONAL",[129],"PHASE1","The primary objective of this trial is to evaluate the safety and tolerability of tarlatamab in combination with ZL-1310 with or without durvalumab and to determine the maximum tolerated combination dose (MTCD) and\u002For recommended phase 2 dose (RP2D) of ZL-1310 in combination with tarlatamab.",[132],"Small Cell Lung Cancer",[32,27,38,134,135,136,137,138],"SCLC","Anti-PD-L1","Extensive Stage Small Cell Lung Cancer","Programmed death protein-1 (PD-1)","Programmed death ligand 1 (PD-L1)","2026-05-27",{"date":141,"type":142},"2026-05-29","ACTUAL",{"date":144,"type":142},"2026-04-21",{"date":146,"type":126},"2031-05-21",{"name":5,"class":6},6]